AJP - Regu AJP: Renal Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 284: R689-R697, 2003. First published November 21, 2002; doi:10.1152/ajpregu.00512.2002
0363-6119/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/3/R689    most recent
00512.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lortie, M. B.
Right arrow Articles by Moon, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lortie, M. B.
Right arrow Articles by Moon, T. W.
Vol. 284, Issue 3, R689-R697, March 2003

The rainbow trout skeletal muscle beta -adrenergic system: characterization and signaling

Michel B. Lortie and Thomas W. Moon

Department of Biology, University of Ottawa, Ottawa, Ontario, Canada K1N 6N5


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The presence and functionality of beta -adrenoceptors (beta -ARs) were examined in red (RM) and white muscle (WM) membranes isolated from the rainbow trout Oncorhynchus mykiss. Specific binding assays revealed the presence of a single class of binding sites with similar affinities in both muscle types (Kd in nM: 0.14 ± 0.03 and 0.18 ± 0.03 for RM and WM, respectively) but with a significantly higher number of binding sites in RM compared with WM (Bmax in fmol/mg protein: 3.22 ± 0.11 and 2.60 ± 0.13, respectively). Selective and nonselective beta -adrenergic agonists (beta -AAs) and antagonists indicated an atypical beta -AR pharmacology. This result may represent a nonmammalian beta -AR classification or, more likely, the presence of more than one beta -AR subtype in trout muscles with similar affinities that could not be kinetically resolved. Adenylyl cyclase (ACase) assays showed a dose-dependent increase in cAMP production as concentrations of beta 2-AAs increased in both muscle membranes with significantly higher basal cAMP production in RM compared with WM (cAMP production in pmol cAMP · mg protein-1 · 10 min-1: 24.67 ± 3.06 and 9.64 ± 3.45, respectively). The agonist-induced increase in cAMP production was blocked by the beta -adrenergic antagonist propranolol, while the ACase activator forskolin increased cAMP production by 7- to 14-fold above basal and ~3-fold above all beta -AAs tested. This study demonstrated the presence of atypical beta 2-ARs on RM and WM membranes of trout, suggesting that beta 2-AAs may be a tool to enhance protein accretion through this signaling pathway.

beta -adrenoceptor; adenylyl cyclase; adenosine 3',5'-cyclic monophosphate; Oncorhynchus mykiss


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

THE ADRENERGIC SYSTEM is key to integrating and modulating many aspects of vertebrate, including fish, metabolism (10). The endogenous circulating catecholamine (CA) hormones epinephrine (Epi) and norepinephrine (NE) exert effects on target cells or tissues by binding to specific hormone receptors called adrenoceptors (ARs) that in turn activate intracellular transduction pathways. Both alpha - and beta -ARs are found on fish and mammalian cells, and the pathways involved in the signal transduction system of fish ARs from the binding of CAs to alpha - and beta -ARs to the ultimate effects of specific enzyme phosphorylation have been studied in isolated tissues, especially hepatocytes (10). Studies on the effects of CAs and the distribution of AR types in other metabolically important fish tissues, however, have received little or no attention. Of all the tissues in fish, skeletal muscle comprises the largest single tissue compartment, representing >50% of total body mass, a larger component when compared with other vertebrates (18). Indeed, there are more total insulin and insulin-like growth factor-I (IGF-I) receptors in skeletal muscle than liver of fish (30).

Pharmacological and molecular studies confirmed the presence of beta 1-, beta 2-, and beta 3-AR subtypes in rat white (glycolytic type II) and red (oxidative type I) skeletal muscles (7, 19, 21, 22, 37). beta 2-Adrenergic agonist (beta 2-AA) binding increased intracellular cAMP concentrations, primarily through the beta 2-AR subtype with slight to no cAMP increase observed using beta 1- and beta 3-AR agonists, respectively (37). Subsequent to changes in cAMP, protein phosphorylation (by protein kinase A) and activation of cAMP-responsive elements (CRE) by cAMP response element binding protein (CREB) are believed to affect protein turnover by a transient stimulation of protein synthesis and a longer-lasting reduction in protein degradation (2, 3, 20, 23-25, 31, 34, 46). However, a mechanistic gap persists between phosphorylation of proteins or activation of CRE by cAMP and subsequent changes in protein turnover (2, 3, 24, 25, 27).

Recent molecular studies demonstrated the presence of a putative beta 2-AR from rainbow trout (Oncorhynchus mykiss) that shared a high degree of amino acid sequence conservation with other vertebrate beta 2-ARs. This AR type was highly expressed in liver, red muscle (RM), and white muscle (WM), but less so in gill, spleen, and kidney with no expression detected in red blood cells (32). No pharmacological characterization of beta -ARs in teleost skeletal muscle is reported or its subsequent coupling to second messengers.

This study tested the hypothesis that rainbow trout RM and WM possess beta 2-ARs, and on beta 2-AA binding, a functional transduction cascade increased production of the second messenger cAMP. The main objectives of this study were to 1) demonstrate the presence of beta -ARs in RM and WM of the rainbow trout, 2) pharmacologically characterize the subtype(s) of beta -AR, and 3) demonstrate the causative association between beta 2-AA binding and activation of the subsequent transduction pathway.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

All animal protocols were reviewed and approved by the University of Ottawa Animal Care Protocol Review Committee and conform with the American Physiological Society "Guiding Principles for Research Involving Animals and Human Beings" (1).

Experimental animals. Female rainbow trout (Oncorhynchus mykiss), weighing approximately 125-200 g, were obtained from Linwood Acres Trout Farm (Campellcroft, ON, Canada). Fish were transported to the University of Ottawa Aquatic Care Facility and were maintained in fiberglass holding tanks (1,275 liters) of well-aerated, dechloraminated City of Ottawa tap water at 13.0 ± 1.0°C. Fish were subjected to a constant 12:12-h light-dark photoperiod and fed five times per week with commercial trout pellets [Martin Mills 5 PT, 5 mm in size and composed of 41.0% crude protein (minimum), 11.0% crude fat (minimum), 3.5% crude fiber (maximum), 1.0% calcium (actual), 0.85% phosphorus (actual), 0.45% sodium (actual), 6,800 IU/kg vitamin A (minimum), 2,100 IU/kg vitamin D (minimum), 80 IU/kg vitamin E (minimum), and 200 IU/kg vitamin C (minimum)]. All experiments used fish acquired in September; receptor characterization experiments were conducted between October and December, and adenylyl cyclase (ACase) experiments were performed in January and February.

Muscle membrane preparation. Rainbow trout were netted and killed by a sharp blow to the head. The skin was removed, and the superficial RM and underlying epaxial WM were quickly and carefully excised, freeze clamped between aluminum blocks cooled in liquid N2, and stored at -80°C until membranes were prepared within 1 wk. Muscle membranes were isolated using a modification of methods previously validated for the rat (17, 21, 36, 39, 42) and the guinea pig (7). The muscle tissue samples were crushed to a fine powder using a porcelain mortar and pestle kept at liquid N2 temperatures. The powder was weighed and suspended in 5 vol of ice-cold basic Hanks' medium (in mM: 136.9 NaCl, 5.4 KCl, 0.8 MgSO4 · 7H2O, 0.33 Na2HPO4 · 7H2O, 0.44 KH2PO4, 5.0 HEPES, 5.0 HEPES-Na, 1.0 NaHCO3, and 0.43 PMSF) adjusted to pH 7.63. All subsequent procedures were carried out on ice (4°C), unless specified otherwise. The muscle was homogenized with six strokes (~10 s/stroke) of a Potter-Elvehjem Teflon-glass homogenizer attached to a commercial drill (Black and Decker) running at low speed. The resulting homogenate was centrifuged at 400 g for 10 min in a Sorvall RC 5B Plus (SS 34 rotor) at 4°C. The supernatant was filtered through nitex nylon mesh (250 µm; Sefar America, Kansas City, MO); the pellet was discarded. The filtrate was centrifuged at 38,000 g for 30 min in the Sorvall RC 5B Plus (SS 34 rotor) at 4°C. The resulting supernatant was discarded, and the final pellet was resuspended in ~2 vol of ice-cold basic Hanks' medium (pH 7.63) and aliquotted into 1.5-ml conical plastic centrifuge tubes. Membranes were frozen in liquid N2 and stored at -80°C until assayed within 2 wk of preparation. The yield of membrane protein was approximately 10-15 and 8-10 mg/g tissue for RM and WM, respectively. A modification of the 5'-nucleotidase assay was used to assess the efficiency of the membrane isolation (40). Enzyme activity was 3.5- to 5-fold higher in the isolated muscle membrane preparation compared with the crude muscle homogenate.

beta -AR characterization. Specific binding assays used established and validated methods previously employed for trout ARs (5). Frozen membranes were thawed on ice. Aliquots of the membrane samples were assayed for protein using the bicinchoninic acid (BCA) assay (Sigma, St. Louis, MO) with BSA as standard and a SPECTRAmax PLUS 384 (Molecular Device, Sunnyvale, CA) microplate spectrophotometer. Protein concentrations were adjusted to 250-350 µg/50 µl based on preliminary experiments showing this concentration provided optimal binding. The radiolabeled, hydrophilic, mixed beta -AR antagonist (-)-4-(3-t-butylamino-2-hydroxypropoxy)-[5,7-3H]benzimidazol-2-one ([3H]CGP-12177A, referred to as [3H]CGP; Amersham Canada, Oakville, ON, Canada; specific activity 46.0 Ci/mmol) was used to characterize beta -AR binding sites. Fifty microliters of trout RM and WM membranes (250-350 µg protein) were incubated in 5-ml polystyrene round-bottom clear tubes (Falcon) for 60 min, a time found to give optimal specific binding, at room temperature (~19°C) in a final volume of 150 µl and in the presence of varying concentrations of [3H]CGP (approximately 0.1 to 5 nM) to estimate total binding, while nonspecific binding was determined in the presence of 10 µM CGP-12177A (CGP; Sigma). All incubations were performed in basic Hanks' (pH 7.63). Binding assays were terminated by aspirating the incubations through a cell harvester (Brandel 24R) onto prerinsed (ice-cold 0.9% NaCl) borosilicate filters (no. 32 Mandel Scientific) and repeated washing (3×) with ice-cold 0.9% NaCl. The membranes collected onto the borosilicate filters were then placed in polyethylene scintillation vials containing 4 ml scintillation cocktail (Safety-Solve; Research Products International, Mount Prospect, IL). The vials were left in the dark for at least 24 h, and the radioactivity was determined using a Beckman Coulter LS6500 multiscintillation counter using automatic quench correction.

Competition assays using 50 µl of muscle membranes (containing 200-300 µg protein) were incubated as above, in the presence of a constant concentration of 1 nM [3H]CGP (~14,500 dpm). Displacement of [3H]CGP was determined in the presence of five concentrations (10, 1, 0.1, 0.01, and 0.001 µM) of beta -adrenergic antagonists [(±)-ICI-118,551 (ICI), atenolol (ATL), (±)-CGP, propranolol (Prop)] or beta -AAs [(±)-dobutamine (Dob), procaterol (Proc), clenbuterol (Clen), ractopamine (Ract), BRL-37,334 (BRL), CL-316,243 (CL), (-)-Epi, and (-)-NE (all from Sigma) except for Ract, provided by Eli-Lilly (Greenfield, IN) and CL, provided by Dr. J. Himms-Hagen, Dept. of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, Univ. of Ottawa] and terminated after a period of 60 min at room temperature. All subsequent manipulations were done exactly as stated in the specific binding assay methodology with the exception that all agonists were kept in tubes wrapped with aluminum foil and assays were carried out in subdued light.

beta -AR coupling to ACase. ACase activity was assayed by adapting methods described for eel liver membranes (10, 12), rockfish enterocyte and brain membranes (26), and rat liver membranes (43). Membrane protein (45-55 µg) was incubated in medium (in mM: 12.5 MgCl2, 5.0 ATP, 20 creatine phosphate, 0.025 GTP, 6.0 theophylline, 50 Tris · HCl, and 6 U/ml creatine phosphokinase and 0.1 mg/ml BSA) in the presence of various beta -AAs [(-)-isoproterenol (Iso), Clen, Ract] and antagonists [Prop, (±)-CGP] and the ACase activator forskolin (FSK). The antagonist Prop was preincubated for 10 min to ensure proper blocking of the ARs. After 10 min at room temperature (~19°C), the reaction was stopped by immersing the tubes in boiling water for 3 min. The samples were subsequently frozen in liquid N2 and stored at -80°C until assayed for cAMP content within 1 wk. As above, the agonists were kept in tubes wrapped with aluminum foil, and assays were carried out in subdued light to prevent photodegradation.

Proteins were precipitated by centrifugation (14,000 g, 5 min, Beckman-Coulter Microfuge R, F241.5 rotor at 4°C). cAMP was determined in supernatants after a modified method that extended the enzyme immunoassay kits from Amersham (Mississauga, ON, Canada) (T. P. Mommsen, personal communication). This included diluting the antiserum (2×) with additional 3,3',5,5'-tetramethylbenzidine substrate solution (TMB substrate; Sigma) and purchasing an additional anti-rabbit IgG-coated plate (Cayman Chemical, Ann Arbor, MI). This permitted doubling the number of analyses per cAMP kit, and preliminary studies validated this procedure. The plates were read at 450 nm with a SPECTRAmax PLUS 384, and the cAMP production was expressed as picomoles cAMP per milligram protein per 10 minutes. Membrane protein was assayed as previously described using the BCA protein assay.

Statistics. Receptor saturation and competition data were analyzed using the EBDA and LIGAND computer programs (28). All further data conversions used Microsoft Excel 2000, graphs were plotted using SigmaPlot 2000 (SPSS, Chicago, IL), and statistical differences were evaluated using appropriate tests with SigmaStat 2.0 (SPSS). A value of P < 0.05 was accepted to indicate significant differences.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

beta -AR characterization. The affinity (Kd) and number (Bmax) of beta -adrenergic binding sites on rainbow trout RM and WM membranes were determined by incubating isolated membranes with increasing concentrations of [3H]CGP (Fig. 1, A and B, respectively). In both tissues, specific binding increased as the concentration of radiolabeled ligand increased to eventually saturate at ~1.5 nM. Specific binding was higher than nonspecific binding up to concentrations near 4 nM and was approximately 0.5 to 3% of total radiolabeled ligand (maximum around 0.5-1 nM of radiolabeled ligand). Nonspecific binding increased linearly and was between 30 and 60% of total binding (lower around 0.5 to 1 nM and higher around 5 nM). Scatchard analyses (Fig. 1C) were linear (EBDA; Ref. 28) and indicated the presence of a homogeneous class of binding sites in both tissues (LIGAND at P < 0.05; Ref. 28). Kd and Bmax values are presented in Table 1. A paired t-test revealed no significant difference between Kd values (P > 0.05) but a significant difference between Bmax values.


View larger version (13K):
[in this window]
[in a new window]
  		Fig. 1.   Radiolabeled saturation curves representing specific binding (SB) assays performed on rainbow trout red (RM; A) and white muscle (WM; B) membranes. Assays contained between 250 and 350 µg protein/50 µl, and incubations were for 60 min with increasing concentrations of 3H-labeled (±)-CGP-12177A ([3H]CGP) in the absence [total binding (TB)] and presence of 10 µM CGP [nonspecific binding (NSB)]. NSB was subtracted from TB at the same CGP concentration to give SB. C: Scatchard plot (EBDA; Ref. 28) of same data for RM and WM membranes. Values represent means ± SE of 6 experiments (each experiment from an individual animal) done in duplicate.


                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Binding affinities and maximum number of binding sites for [3H]CGP (beta -adrenoceptors) on rainbow trout red and white muscle membranes

Competition assays were performed using classic mammalian AR agonists [Fig. 2, A (RM) and C (WM)] and antagonists [Fig. 2, B (RM) and D (WM)]. The mammalian antagonists classified as mixed beta -antagonists, CGP and Prop, displaced [3H]CGP to ~30% of total binding at the highest concentration used (10 µM). The beta 2-antagonist ICI and the beta 2-agonists Clen and Ract were less effective and displaced to <50% of total binding. The endogenous adrenergic agonists Epi and NE both displaced to ~60% of total binding with a slightly higher displacement by Epi. The remaining agonists and antagonists displaced to <60% of total binding, although quantitative differences were noted between Dob (a beta 1-agonist) and Proc (a beta 2-agonist) displacement in RM and WM (Fig. 2, A and C).


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 2.   Displacement curves representing competition between CGP and various adrenoceptor (AR) agonists and antagonists performed on rainbow trout RM [agonists (A) and antagonists (B)] and WM [agonists (C) and antagonists (D)] membranes. Assays contained between 250 and 350 µg protein/50 µl, and incubations were for 60 min at a constant concentration of 1 nM [3H]CGP in the absence (TB) and presence of 5 concentrations (10, 1, 0.1, 0.01, and 0.001 µM) of agonists [(-)-epinephrine (Epi), (-)-norepinephrine (NE), clenbuterol (Clen), ractopamine (Ract), procaterol (Proc), dobutamine (Dob), BRL-37,334 (BRL), and CL-316,243 (CL)] and antagonists [(±)-ICI-118,551 (ICI), atenolol (ATL), propranolol (Prop), and CGP]. Values represent means of 4 experiments (each experiment from an individual animal) done in duplicate. Variations (approximately ±5%) for individual data points are omitted for clarity.

The concentration of ligands causing 50% displacement of specific binding (Ki) was determined using EBDA (Table 2). The Ki values for the agonists were in the following order: Clen approx  Ract > Proc approx  NE approx  Dob approx  Epi with no significant displacement by BRL or CL in the RM, and Clen approx  Ract > Epi approx  NE > Proc > BRL with no significant displacement by Dob or CL in the WM. The Ki values for the antagonists were in the following order: CGP > Prop > ICI, with no significant displacement by ATL in RM or WM membranes.

                              
View this table:
[in this window]
[in a new window]
  		Table 2.   Competitive displacement parameters (Ki) for [3H]CGP in rainbow trout red and white muscle membranes using various agonists and antagonists

beta -AR coupling to ACase. ACase assays were performed on trout RM and WM membranes, and cAMP production was assessed. Assays used increasing concentrations of beta 2-agonists [Fig. 3, A (RM) and B (WM)], and in the presence of 1 µM beta 2-agonists with and without 100 µM of the general beta -antagonist Prop [Fig. 4, A (RM) and B (WM)]. Basal activities of RM cAMP production (means ± SE in pmol cAMP · mg protein-1 · 10 min-1) were 24.7 ± 3.1, and the beta 2-agonists significantly increased cAMP production at a concentration of 1 µM Clen and Ract (Fig. 3A). Similarly, WM basal values of cAMP production were 9.6 ± 3.5, and production increased significantly at concentrations of 0.1 and 0.01 µM Clen and Ract, respectively (Fig. 3B). The production of cAMP increased in a dose-dependent manner up to 10 µM Clen and Ract. The fold change in RM and WM membrane ACase activities was approximately 2.4 and 6.5, respectively, comparing basal with activities at 10 µM agonist. This difference in fold increase is due to a significantly lower basal activity of ACase in WM compared with RM, as activities in the muscle membranes at 10 µM agonists were the same.


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 3.   RM (A) and WM (B) membrane cAMP production at increasing concentrations of the adrenergic agonists Clen and Ract. Assays containing 45-55 µg protein were incubated for 10 min in the presence or absence of agonists. Means ± SE are presented for 4 independent experiments (each experiment from an individual animal) measured in duplicate. Levels of significance (repeated-measures 1-way ANOVA, P < 0.05) for increasing concentrations of Clen and Ract compared with basal values are represented by dagger  and Dagger , respectively (A and B). There is a significant difference in basal cAMP production between RM and WM membranes (paired t-test, P < 0.05).



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of 10 µM forskolin (FSK) and 1 µM concentrations of various adrenergic agonists [Clen, Ract, and (-)-isoproterenol (Iso)] with or without 10 µM concentration of the adrenergic antagonist Prop on RM (A) and WM (B) membrane adenylyl cyclase activities. Assays containing 45-55 µg protein were incubated for 10 min in the presence or absence of agonists, while those incubated with the antagonist Prop were preincubated for 5 min before 10-min incubation with the agonists. Means ± SE are presented for 4 independent experiments (each experiment from an individual animal) measured in duplicate. Levels of significance compared with basal or Prop alone and agonist plus Prop are represented by * and black-lozenge , respectively (A and B). There is a significant difference in basal cAMP production between RM and WM membranes (paired t-test, P < 0.05).

Incubating membranes with 1 µM beta 2-agonists (Clen, Ract, and Iso) significantly increased cAMP production in both RM (Fig. 4A) and WM (Fig. 4B) membranes. Preincubating with 100 µM Prop for 10 min completely blocked these significant agonist-induced increases. No significant differences existed between basal and Prop alone, or between basal, Prop alone, and Prop plus the beta 2-AAs (Clen, Ract, and Iso). Interestingly, there were no significant differences between any of the beta 2-AAs within a muscle type or between RM and WM; there was, however, a significant difference between basal ACase activities in RM and WM as noted in Fig. 3, but this difference is eliminated by incubation of the membranes with Prop alone. The beta -antagonist CGP was also tested with and without Prop, and no significant differences in cAMP production were observed in either membrane type (data not shown). Additionally, an ACase activator, FSK (10 µM), significantly increased cAMP production by approximately 7- and 14-fold above basal in RM and WM membranes, respectively (Fig. 4, A and B). This represents approximately a three-fold greater activation than observed for any of the agonists used. cAMP production in the presence of FSK was not significantly different between RM and WM membranes.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The main objectives of this study were to demonstrate the presence of beta -ARs in RM and WM of the rainbow trout, pharmacologically determine the beta -AR subtype(s) present, and show a causative association between beta -AA binding and the activation of the subsequent signaling pathway. beta -Adrenergic binding sites and increased cAMP production on beta 2-AA binding have been characterized in mammalian red (oxidative type I) and white (glycolytic type II) skeletal muscles. However, this study is the first characterization of beta -adrenergic binding sites and coupling to cAMP in skeletal muscles of a teleost fish.

beta -AR characterization. The use of different radioactive ligands ([3H]CGP, [3H]dihydroalprenolol, and [125I]iodocyanopindolol) and different muscle preparations makes it difficult to compare these fish studies with previous studies. However, Jenson et al. (17) used membranes isolated from adult and juvenile rats and the radioligand [3H]CGP and reported similar results as shown here. In adult rat membranes, CGP affinity (Kd in nM) was 0.37 and 0.31 and the number of binding sites (Bmax in fmol/mg protein) was 9.38 and 4.74 in red (soleus) and white (extensor digitorum longus) skeletal muscles, respectively. Similarly, these values in juvenile rat membranes were Kd values (in nM) of 0.27 and 0.24 and Bmax values (in fmol/mg protein) of 11.21 and 5.45 in red (soleus) and white (epitrochlearis) skeletal muscles, respectively. Red skeletal muscle membranes had similar binding affinity but double the number of binding sites compared with WM in both adult and juvenile rats. Comparing these values reported in rats with those of trout RM and WM (Table 1) indicates slightly higher affinities in trout but approximately two- to five-fold lower Bmax values. The trend of higher binding site numbers in RM compared with WM was retained, as reported in other mammalian studies that used other radiolabeled ligands and/or preparations (13, 21, 33, 45). Possible contamination by vascular tissue is considered to be an insignificant contributing factor to the higher binding site numbers in RM compared with WM because <3% of the RM volume is vascular tissue (6). The smaller number of cell surface hormone receptors in fish compared with mammals is a consistent observation reported for other receptor types (30).

Furthermore, comparing the values obtained from trout RM and WM (Table 1) with the literature for rainbow trout liver, heart muscle, and red blood cell beta -ARs reveals some differences. Compared with the liver, RM and WM had slightly higher affinity (or lower Kd values) (approximately 0.16 vs. 0.4 nM) but threefold lower Bmax values (approximately 3 vs. 9 fmol/mg protein; Ref. 9). RM and WM had very similar Kd values to heart muscle (14, 15) but Bmax values about eight-fold lower (3 vs. 24 fmol/mg protein; Ref. 14). RM and WM had much higher affinity (lower Kd values) than red blood cell (~0.16 nM vs. 2.5-4 nM; Refs. 16, 35). No comparable Bmax values are available as the binding assays were performed on whole cells, and therefore values are expressed as number of binding sites per cell.

Despite the much higher number of binding sites in liver and heart muscle, skeletal muscle comprises ~50% of the total body weight (14) compared with ~1% for liver (5) and 0.15% for heart. This difference between tissue masses renders the skeletal muscle a metabolically important target for CAs that needs further attention.

Previous studies reported mainly beta 2-ARs and possibly beta 1-ARs on adult and juvenile rat skeletal muscles (17, 21) with some reports of beta 3-ARs on mammalian skeletal muscle membranes (36, 39, 41). Competition assays using classic mammalian beta -AR agonists and antagonists and rainbow trout RM and WM membranes revealed the presence of an atypical beta 2-AR pharmacology (Fig. 2, Table 2). The order of potency for the antagonists (CGP > Prop > ICI with no displacement by ATL) clearly showed typical beta 2-AR characteristics in both trout muscle membranes. The mixed beta -AR antagonists CGP and Prop displaced the most effectively, closely followed by the beta 2-AR antagonist ICI, but no displacement with the beta 1-AR antagonist ATL. However, the order of potency for the agonists in both trout RM and WM was ambiguous and would suggest an atypical behavior. In RM (Clen approx  Ract > Proc approx  NE approx  Dob approx  Epi with no displacement by BRL and CL), the beta 2-AAs Clen, Ract, and Proc displaced the most effectively, supporting the antagonist result. The slightly higher affinity of NE compared with Epi supports beta 1-AR characteristics (25). Also, some displacement by the beta 1-AA Dob indicated the presence of beta 1-AR characteristics. Similarly, in trout WM (Clen approx  Ract > Epi approx  NE > Proc > BRL with no displacement by Dob and CL), the beta 2-AAs Clen and Ract displaced best, which again supported the results of the antagonist experiments. However, the beta 2-AA Proc would be expected to displace better than the endogenous CAs, but does not. Epi had a slightly higher affinity than NE, again supporting the presence of the beta 2-AR subtype. Also, some displacement by the beta 3-AA BRL would support a beta 3-AR component. This study is not the first to report ambiguities when using mammalian pharmacological agents in nonmammalian organisms, and this may indicate nonmammalian pharmacological classification (10).

The order of potency in hepatic membranes of the rainbow trout (Ref. 32; S. G. Dugan, personal communication) for the antagonists (CGP > ICI with no displacement by ATL) and the agonists (Clen > Epi > Proc > Ract with no displacement by NE and Dob) both supported a strict beta 2-AR pharmacology in the liver. Some quantitative differences exist between agonist and antagonist displacement in trout liver and muscle, but in general trends were similar. The most significant differences were much lower Ki values for Ract in muscle (~120 nM) than liver (7,090 nM; S. G. Dugan, personal communication) and lower values for ICI and Proc displacement in the muscles compared with the liver. Also, NE displaced in both RM and WM but not in liver, and Dob displaced in RM but not in WM or liver. This may be evidence for the presence of more than one beta -AR (beta 1-, beta 2-, and/or beta 3-ARs) with similar affinities, because the Scatchard analysis (Fig. 1C) revealed only a single class of binding sites over the range of concentration used in the specific binding assays. In cattle, competitive ligand binding studies supported the presence of beta 1- and beta 2-ARs, but saturation analysis indicated one binding site without distinguishing between them (38). Furthermore, studies in pig and rodent reported Ract to have slightly less affinity for beta 1- compared with beta 2-ARs (4, 27). The higher CGP affinities found in RM and WM compared with liver that appeared to be exclusively beta 2-AR support the existence of more than one muscle beta -AR subtype. In fact, molecular evidence indicates the expression of a rainbow trout putative beta 2-AR in liver and in both RM and WM (32), while a rainbow trout putative beta 3-AR is expressed in RM and WM but not liver (J. G. Nickerson, personal communication). Therefore, the results of the agonist displacement studies need to be evaluated with caution, as it is possible that more than one beta -AR exists in fish muscle as in mammalian skeletal muscle. Also, the coupling of these different subtypes to the signal transduction pathway could be different as demonstrated in rat muscle (37).

Interestingly, the two beta 2-AAs, Clen and Ract, used in studies to enhance muscle growth in the meat industry (mammals and fish; Refs. 2, 29, 43, 44) displaced the radiolabeled ligand [3H]CGP with high affinity. Binding of these two beta 2-AAs to rainbow trout muscle membrane beta -ARs would imply possible direct effects of these growth supplements on skeletal muscle and the need for further investigations of these agents for use in the aquaculture industry.

beta -AR coupling to ACase. To establish coupling between beta -AR occupancy and the receptor transduction pathway, the production of cAMP was determined. This study used the ACase/cAMP assay on muscle membrane preparations (similar to studies done in hepatic membranes of fish; Refs. 8, 9, 11, 12) rather than whole muscle or transverse muscle slices commonly used in mammalian studies due to the anatomic differences between fish and mammalian skeletal muscles (18). As a result, direct comparisons of cAMP production rates between this study and the mammalian literature are difficult to make, but obvious qualitative comparisons are possible. Roberts and Summers (37), using soleus muscle slices from young rats, reported dose-dependent cAMP production with the beta 2-AA (-)-Iso with 50% maximum response (at 10 µM) reached at concentrations of 10-100 nM. Clen and Ract in both RM and WM membranes of the rainbow trout (Fig. 3, A and B, respectively) increased cAMP concentrations, but saturation at 10 µM was not achieved. The nonselective beta -adrenergic antagonist Prop blocked cAMP production in RM and WM of trout (Fig. 4, A and B, respectively), as reported in mammalian studies. FSK, which directly stimulated mammalian ACase independent of the hormone receptor (47), activated mammalian ACase by seven- to eightfold at 10 µM compared with values reached using 10 µM Iso. RM and WM membranes from the trout are stimulated by FSK at a concentration of 10 µM about three-fold above values reached using 1 µM Clen, Ract, or Iso and 7- to 14-fold above basal cAMP production. The difference in potency of FSK between trout and mammalian ARs may reflect the specificity of FSK for ACase in the two experiments but also the tissue preparation, optimization of the various agents in the two preparations, the coupling between the AR and ACase, and the actual amount of ACase.

Studies in fish liver reported basal ACase/cAMP activities (in pmol cAMP · mg protein-1 · 10 min-1) of 20, 40, and 7.6 and stimulated activities (1-10 µM Epi) of 40-50, 63, and 20.5 in American eel (10, 12), bullhead catfish (8), and rainbow trout (9), respectively. In comparison, basal values in trout RM were similar to eel while WM basal values were more similar to rainbow trout liver activities. Stimulated values (1 µM Iso) in RM and WM were similar to bullhead liver stimulated values. These levels of agonist-stimulated cAMP production in RM and WM were obtained with 10 times less agonist compared with liver. As the number of liver beta 2-ARs is about three-fold higher per gram tissue than in the muscle, the coupling between the ARs and ACase in muscle may be altered compared with that in liver.

It is interesting that RM had significantly higher basal rates of ACase activities compared with WM. However, this trend was abolished in samples incubated with the antagonist Prop and the ACase activator FSK. We know of no similar observation in the mammalian literature, but coupled with the higher number of beta -ARs in RM, it may indicate a greater sensitivity or amplification of the message conveyed by Epi, NE, or any beta -AA to ACase in RM than in WM.

In conclusion, rainbow trout RM and WM membranes possess a single class of saturable beta -adrenergic [3H]CGP binding sites. A significantly greater number of CGP binding sites are located in RM compared with WM. These binding sites had an atypical beta 2-AR pharmacology as determined using mammalian beta -adrenergic agonists and antagonists. This result implicates the presence of more than a single beta -AR subtype in these muscles as preliminary molecular biology evidence indicates. The rainbow trout muscle beta -AR transduces its cellular message through a G protein, ultimately activating the ACase/cAMP pathway. The increased cAMP production on stimulation with beta 2-AAs was dose dependent and blocked using the antagonist Prop.

Perspectives

This study is the first to report the presence of functional beta 2-ARs and the causative association between beta 2-AA binding and subsequent receptor specific transduction in RM and WM of a fish. The precise effects of reduced or elevated levels of the second messenger cAMP need further investigation especially with respect to changes in muscle protein synthesis and degradation. Recent studies, mostly in mammals and a few in birds, reported increased protein synthesis and decreased protein degradation, resulting in an increased muscle protein accretion after treatments with beta 2-AAs. In mammalian muscle, convincing evidence exists that the effects of beta 2-AAs are mediated directly on the target tissues through a beta 2-AR, and the intricate details of the cellular signaling pathway involved are being investigated, including cAMP, protein phosphorylation (via protein kinase A), and activation of CREs by CREB (3, 25, 27). The presence of a functional muscle beta 2-AR system in the rainbow trout provides an excellent fish model to evaluate the impact of beta 2-AA treatments on fish muscle growth. Finally, this study provides important basic knowledge of beta -AR function in the muscles of an early branching vertebrate and suggests potentially beneficial applications to the aquaculture industry.


    ACKNOWLEDGEMENTS

We thank J. Nickerson and S. Dugan for the use of their unpublished experimental data in this paper and fruitful discussions during the writing of this paper; Dr. J. Himms-Hagen for providing CL-316,243; and Eli-Lilly (Greenfield, IN) for providing the ractopamine.


    FOOTNOTES

This study was supported by funds from the Natural Sciences and Engineering Research Council of Canada to T. W. Moon and by the Government of Ontario-University of Ottawa Graduate Scholarship in Science and Technology research scholarship to M. B. Lortie.

Address for reprint requests and other correspondence: T. W. Moon, Dept. of Biology, 150 Louis Pasteur, Univ. of Ottawa, Ottawa, Ontario K1N 6N5, Canada (E-mail: tmoon{at}science.uottawa.ca).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published November 21, 2002;10.1152/ajpregu.00512.2002

Received 26 August 2002; accepted in final form 18 November 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 283: R281-R283, 2002[Free Full Text].

2.   Beermann, DH. beta -Adrenergic agonists and growth. In: The Endocrinology of Growth, Development and Metabolism in Vertebrates, edited by Schreibman MP, Scanes CG, and Pang PKT. New York: Academic, 1993, vol. 15, p. 345-366.

3.   Beermann, DH. beta -Adrenergic receptor agonist modulation of skeletal muscle growth. J Anim Sci 80: E18-E23, 2002[Abstract/Free Full Text].

4.   Colbert, WE, Williams PD, and Williams GD. beta -Adrenoceptor profile of ractopamine HCl in isolated smooth and cardiac muscle tissues of rat and guinea-pig. J Pharm Pharmacol 43: 844-847, 1991[Web of Science][Medline].

5.   Dugan, SG, and Moon TW. Cortisol does not affect hepatic alpha - and beta -adrenoceptor properties in rainbow trout (Oncorhynchus mykiss). Fish Physiol Biochem 18: 343-352, 1998.

6.   Egginton, S, Cordiner S, and Skilbeck C. Thermal compensation of peripheral oxygen transport in skeletal muscle of seasonally acclimatized trout. Am J Physiol Regul Integr Comp Physiol 279: R375-R388, 2000[Abstract/Free Full Text].

7.   Elfellah, MS, and Reid JL. Identification and characterization of beta -adrenoceptors in guinea pig skeletal muscle. Eur J Pharmacol 139: 67-72, 1987[Web of Science][Medline].

8.   Fabbri, E, Brighenti L, Ottolenghi C, Puviani AC, and Capuzzo A. beta -Adrenergic receptors in catfish liver membranes: characterization and coupling to adenylate cyclase. Gen Comp Endocrinol 85: 254-260, 1992[Web of Science][Medline].

9.   Fabbri, E, Capuzzo A, Gambarotta A, and Moon TW. Characterization of adrenergic receptors and related transduction pathways in the liver of the rainbow trout. Comp Biochem Physiol 112B: 643-651, 1995.

10.   Fabbri, E, Capuzzo A, and Moon TW. The role of circulating catecholamines in regulation of fish metabolism: an overview. Comp Biochem Physiol 120C: 177-192, 1998.

11.   Fabbri, E, Gambarotta A, and Moon TW. Adrenergic signaling and second messenger production in hepatocytes of two fish species. Gen Comp Endocrinol 99: 114-124, 1995[Web of Science][Medline].

12.   Fabbri, E, Selva C, Moon TW, and Capuzzo A. Characterization of [3H]CGP 12177 binding to beta -adrenergic receptors in intact eel hepatocytes. Gen Comp Endocrinol 121: 223-231, 2001[Web of Science][Medline].

13.   Fell, RD, Lizzo FH, Cervoni P, and Crandall D. Effect of contractile activity on rat skeletal muscle beta -adrenoceptor properties. Proc Soc Exp Biol Med 180: 527-532, 1985[Medline].

14.   Gamperl, AK, Vijayan MM, Pereira C, and Farrell AP. beta -Receptors and stress protein 70 expression in hypoxic myocardium of rainbow trout and chinook salmon. Am J Physiol Regul Integr Comp Physiol 274: R428-R436, 1998[Abstract/Free Full Text].

15.   Gamperl, AK, Wilkinson M, and Boutilier RG. beta -Adrenoceptors in the trout (Oncorhynchus mykiss) heart: characterization, quantification, and effects of repeated catecholamine exposure. Gen Comp Endocrinol 95: 259-272, 1994[Web of Science][Medline].

16.   Gilmour, KM, Didyk NE, Reid SG, and Perry SF. Downregulation of red blood cell beta -adrenoceptors in response to chronic elevation of plasma catecholamine levels in the rainbow trout. J Exp Biol 186: 309-314, 1994[Web of Science][Medline].

17.   Jenson, J, Brors O, and Dahl HA. Different beta -adrenergic receptor density in different rat skeletal muscle fiber types. Pharmacol Toxicol 76: 380-385, 1995[Web of Science][Medline].

18.   Johnston, IA. Physiology of muscle in hatchery raised fish. Comp Biochem Physiol 73B: 105-124, 1982.

19.   Kaumann, AJ, and Molenaar P. Modulation of human cardiac function through 4 beta -adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 355: 667-681, 1997[Web of Science][Medline].

20.   Kim, YS, and Sainz RD. beta -Adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 50: 397-407, 1991[Web of Science].

21.   Kim, YS, Sainz RD, Molenaar P, and Summers RJ. Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles. Biochem Pharmacol 42: 1783-1789, 1991[Web of Science][Medline].

22.   Liggett, SB, Shah SD, and Cryer PE. Characterization of beta -adrenergic receptors of human skeletal muscle obtained by needle biopsy. Am J Physiol Endocrinol Metab 254: E795-E798, 1988[Abstract/Free Full Text].

23.   Mersmann, HJ. Overview of the effects of beta -adrenergic agonists on animal growth including mechanisms of action. J Anim Sci 76: 160-172, 1998[Abstract/Free Full Text].

24.   Mills, SE. Biological basis of the ractopamine response. In: Ractopamine at One Year of Commercial Application. Indianapolis, IN: International Animal Agriculture and Food Science Conference, 2001 (http://www.fass.org/fass01/pdfs/Mills.pdf).

25.   Mills, SE. Implications of feedback regulation of beta -adrenergic signaling. J Anim Sci 80: E30-E35, 2002[Abstract/Free Full Text].

26.   Mommsen, TP, and Mojsov S. Glucagon-like peptide-1 activates the adenylyl cyclase system in rockfish enterocytes and brain membranes. Comp Biochem Physiol 121B: 49-56, 1998.

27.   Moody, DE, Hancock DL, and Anderson DB. Phenetholamine repartitioning agents. In: Farm Animal Metabolism and Nutrition, edited by D'Mello JPF. Wallinford, UK: CAB International, 2000, vol. 4, p. 65-96.

28.   Munson, PF, and Rodhard D. LIGAND: a versatile computerized approach for characterization of ligand-binding system. Anal Biochem 107: 220-239, 1980[Web of Science][Medline].

29.   Mustin, WT, and Lovell RT. Feeding the repartitioning agent ractopamine to channel catfish (Ictalurus punctatus) increases weight gain and reduces fat deposition. Aquaculture 109: 145-152, 1993[Web of Science].

30.   Navarro, I, Leibush B, Moon TW, Plisetskaya EM, Baños N, Méndez E, Planas JV, and Gutiérrez J. Insulin, insulin-like growth factor-I (IGF-I) and glucagons: the evolution of their receptors. Comp Biochem Physiol 122B: 137-153, 1999.

31.   Navegantes, LCC, Resano NMZ, Migliorini RH, and Kettelhut IC. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. Am J Physiol Endocrinol Metab 280: E663-E668, 2001.

32.   Nickerson, JG, Dugan SG, Drouin G, and Moon TW. A putative beta 2-adrenoceptor from the rainbow trout (Oncorhynchus mykiss). Molecular characterization and pharmacology. Eur J Biochem 268: 6465-6472, 2001[Web of Science][Medline].

33.   Polla, B, Cappelli V, Morello F, Pellegrino MA, Boschi F, Pastoris O, and Reggiani C. Effects of the beta 2-agonist clenbuterol on respiratory and limb muscles of weaning rats. Am J Physiol Regul Integr Comp Physiol 280: R862-R869, 2001[Abstract/Free Full Text].

34.   Reeds, PJ, and Mersmann HJ. Protein and energy requirements of animals treated with beta -adrenergic agonists: a discussion. J Anim Sci 69: 1532-1550, 1991[Abstract].

35.   Reid, SD, Moon TW, and Perry SF. Characterization of beta -adrenoceptors of rainbow trout (Oncorhynchus mykiss) erythrocytes. J Exp Biol 158: 199-216, 1991[Abstract/Free Full Text].

36.   Roberts, SJ, Molenaar P, and Summers RJ. Characterisation of propanolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle. Br J Pharmacol 109: 344-352, 1993[Web of Science][Medline].

37.   Roberts, SJ, and Summers RJ. Cyclic AMP accumulation in rat soleus muscle: stimulation by beta 2- but not beta 3-adrenoceptors. Eur J Pharmacol 348: 53-60, 1998[Web of Science][Medline].

38.   Sillence, MN, and Matthews ML. Classical and atypical binding sites for beta -adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes. Br J Pharmacol 111: 866-872, 1994[Web of Science][Medline].

39.   Sillence, MN, Moore NG, Pegg GG, and Lindsay DB. Ligand binding properties of putative beta 3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes. Br J Pharmacol 109: 1157-1163, 1993[Web of Science][Medline].

40.   Solymon, A, and Trams EG. Enzyme markers in characterization of isolated plasma membranes. Enzyme 13: 329-372, 1972[Web of Science][Medline].

41.   Summers, RJ, Russell FD, Roberts SJ, Bonazzi VR, Sharkey A, Evans BA, and Molenaar P. Localisation and characterisation of atypical beta -adrenoceptors in skeletal muscle and gut. Pharmacol Commun 6: 237-252, 1995.

42.   Unson, CG, Cypess AM, Wu CR, Goldsmith PK, Merrifield RB, and Sakmar TP. Antibodies against specific extracellular epitopes of glucagon receptor block glucagon binding. Proc Natl Acad Sci USA 93: 310-315, 1996[Abstract/Free Full Text].

43.   Vandenbergh, GW, Leatherland JF, and Moccia RD. The effects of the beta -agonist ractopamine on growth hormone and intermediary metabolite concentrations in rainbow trout, Oncorhynchus mykiss (Walbaum). Aquacul Res 29: 79-87, 1998.

44.   Vandenbergh, GW, and Moccia RD. Growth performance and carcass composition of rainbow trout, Oncorhynchus mykiss (Walbaum), fed the beta -agonist ractopamine. Aquacul Res 29: 469-479, 1998.

45.   Williams, RL, Caron MG, and Daniel K. Skeletal muscle beta -adrenergic receptors: variations due to fiber type and training. Am J Physiol Endocrinol Metab 246: E160-E167, 1984[Abstract/Free Full Text].

46.   Yang, YT, and McElligott MA. Multiple actions of beta -adrenergic agonists on skeletal muscle and adipose tissue. J Biochem 261: 1-10, 1989.

47.   Zhang, G, Lui Y, Ruoho AE, and Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature 386: 247-253, 1997[Medline].

Am J Physiol Regul Integr Comp Physiol 284(3):R689-R697
0363-6119/03 $5.00 Copyright © 2003 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Frolow and C. L. Milligan
Hormonal regulation of glycogen metabolism in white muscle slices from rainbow trout (Oncorhynchus mykiss Walbaum)
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1344 - R1353.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. G. Nickerson, S. G. Dugan, G. Drouin, S. F. Perry, and T. W. Moon
Activity of the unique {beta}-adrenergic Na+/H+ exchanger in trout erythrocytes is controlled by a novel {beta}3-AR subtype
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R526 - R535.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/3/R689    most recent
00512.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lortie, M. B.
Right arrow Articles by Moon, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lortie, M. B.
Right arrow Articles by Moon, T. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online